October 07, 2026

FDA grants Temab-A dual Breakthrough status

The designations cover refractory metastatic CRC and previously treated c-Met–expressing NSCLC.

MDSpire News

October 01, 2026

AI diagnostics and what clinicians can verify in oncology

"The more AI changes what we do … the less able we are to check it.”

MDSpire News

September 30, 2026

Misleading AI summaries may alter recall

Participants exposed to inaccurate postevent summaries were less likely to correctly remember key details from videos they had previously watched.

MDSpire News

September 30, 2026

Vitamin D may ease cancer treatment skin toxicity

Most patients reported symptom relief within 10 days, while 73% continued anticancer therapy without interruption.

MDSpire News

September 29, 2026

Dietary fat type may matter after prostate cancer

The association was driven by cardiovascular disease and other cancers, not prostate cancer mortality.

MDSpire News

September 28, 2026

Trends in alcohol-linked cancer mortality

Investigators examined 3 decades of US cancer mortality estimates across age, sex, region, and cancer type.

MDSpire News

September 28, 2026

ACS report: Lung cancer deaths plunge as survival doubles

Lung cancer deaths fell by more than half among US males as smoking declined, earlier-stage diagnoses increased, and 5-year relative survival doubled.

MDSpire News

September 25, 2026

FDA monthly preview: Key October decisions to watch

Several FDA decisions across multiple specialties are expected this month.

MDSpire News

September 24, 2026

FDA approves combo for advanced renal cell carcinoma

Median progression-free survival was 15 months with the combination vs. 11 months with cabozantinib in the LITESPARK-011 trial.

MDSpire News

September 24, 2026

FDA clears targeted cholangiocarcinoma therapy

In the single-arm REFOCUS trial, 46% of patients responded to treatment, with a median response duration of 11.8 months.

MDSpire News